Show simple item record

dc.contributor.authorBanerjee, Sen_US
dc.contributor.authorGonzalez-Martin, Aen_US
dc.contributor.authorHarter, Pen_US
dc.contributor.authorLorusso, Den_US
dc.contributor.authorMoore, KNen_US
dc.contributor.authorOaknin, Aen_US
dc.contributor.authorRay-Coquard, Ien_US
dc.date.accessioned2021-01-18T14:22:24Z
dc.date.issued2020-11en_US
dc.identifier.citationESMO open, 2020, 5 (6)en_US
dc.identifier.issn2059-7029en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4291
dc.identifier.eissn2059-7029en_US
dc.identifier.doi10.1136/esmoopen-2020-001110en_US
dc.description.abstractPoly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines Agency and Food and Drug Administration approval of olaparib as first-line maintenance therapy in patients with <i>BRCA1/2</i> mutation, establishing a new standard of care. Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond patients with <i>BRCA1/2</i> mutations and as combination strategies were presented in 2019, leading to the recent approval of maintenance niraparib irrespective of biomarker status and olaparib in combination with bevacizumab in homologous recombination deficiency-positive-associated advanced ovarian cancer. An <i>ESMO Open - Cancer Horizons</i> round-table expert panel discussed the four phase III trials of first-line PARP inhibitor therapy and how they are changing the clinical management of advanced ovarian cancer.en_US
dc.formatPrinten_US
dc.languageengen_US
dc.language.isoengen_US
dc.titleFirst-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons</i> round-table discussion.en_US
dc.typeJournal Article
dcterms.dateAccepted2020-11-25en_US
rioxxterms.versionofrecord10.1136/esmoopen-2020-001110en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0en_US
rioxxterms.licenseref.startdate2020-11en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfESMO openen_US
pubs.issue6en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume5en_US
pubs.embargo.termsNo embargoen_US
dc.contributor.icrauthorBanerjee, Susanaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record